Conference Day Two: 19th May 2009

08.45 Chairperson’s Opening Remarks

08.50 The Contemporary High Throughput Screening Collection: Design And Assembly

• Describing how the design of today’s screening collection has evolved
• Operating a HTS screening collection that suits today’s screening strategies
• Collection content: Outsourcing vs. Internal High Throughput Chemistry
• Synthesis of unique pharmacophores
• Quality Control of a HTS collection
• How CM can contribute to assembling and operating a successful collection

Dr Stevan W Djuric
Senior Director, Global Pharmaceutical R&D, Advanced Technology, Medicinal Chemistry Technologies and Structural Chemistry
Abbott

09.30 Identification Of Additional Synergies Between CM And Other Drug Discovery Departments

• Analysing data and current workflows to implement improvements in logistical and information workflows between CM and HTS and other discovery departments
• New protocols that ensure minimal steps from CM to screening
• Developing CM services for additional discovery departments
• Compound sourcing strategies and management

Jaco Koobs
Compound Sourcing Manager
Nycomed

10.40 Sourcing Innovative Compounds To Fulfil Drug Discovery Needs

• Compound purchasing: Identifying the right compounds for our library
• Commissioned synthesis: Key challenges working with external partners and getting the results we want
• Chemistry outsourcing: Building a small molecule screening collection
• Addressing compound attrition in later stages and how it impacts compound collection strategies
• Small molecule screening in context to other screening technologies like encoded libraries and fragment based drug discovery

Duncan Judd
Manager, Molecular Discovery Research
GlaxoSmithKline

11.20 Outsourcing Compound Inventory Case Study

• Motivations for working with an external collaborator
• Implementation of the store
• Integration of the new company
• IP issues associated with outsourcing activity

Dr Sylviane Boucharens
Section Head, Molecular Pharmacology
Schering-Plough Corporation

13.00 Improving Compound Management Through New Technology And Library Enhancement

Elan Pharmaceuticals is a research driven, medium size bio-pharmaceutical company. As a result of the desire to explore new hypotheses, the Compound Management needs to constantly grow and adapt. Particular challenges are experienced with compound enhancement to ensure the most relevant available collection, compound supply for screening and crystallography groups, and logistics necessary to adhere to acceptable data tracking. This talk will provide an overview of the steps taken to complete this process using new technology and current personnel. As a medium sized pharmaceutical company, the problems encountered were not able to be solved using brute force or increase in the number of instruments purchased.

• Implementing a new CM strategy using advanced technology and concepts to yield scalable and adaptable processes for future use
• Key deliverables identified included providing flexible services supplying HTS, X-ray and focused screening groups which resulted in a 90% reduction in non-assay ready plates delivered and resulting reduction of compound waste
• Identifying, acquiring and integration of approximately 80,000 new compounds to the Elan compound collection
• Physically incorporating the selected compounds into the screening library and ensuring the data flow of information was not compromised
• Monitoring new compounds closely to help future library enhancement projects that may provide the most useful and relevant additions to Elan research initiatives

Michael Jobling
Head of Compound Management
Elan Pharmaceuticals

13.40 Panel Discussion: Best Practices Working With External Collaborators

• Examining opportunities for outsourcing CM activities
• Discussing critical criteria and qualifications for partners
• Rigorous methods for overseeing vendors and monitoring performance
• Managing risk associated with outsourcing activities
• Creating win-win partnerships that result in open dialogue and improved operations

Panelists:

15.30 University Of Dundee Compound Management Case Study

• Developing a large, rich compound inventory for use in an academic setting
• Compound handling for successful drug discovery in Tropical diseases
• Using our experience to develop additional chemical tools for new targets
• Working with external collaborators
• Planning for acoustic dispensing

Irene Hallyburton
Compound Manager
University of Dundee

14.50 Instilling Quality And Flexibility Within A Lead Optimisation Organisation

• Describing key lean principles assessed and applied to sample management to facilitate compound flow, high quality product and flexibility within this system
• Quality operations: Demonstrated by screening data and the improvements made within both Screening and Sample Management organisations
• Using small, stand-alone liquid handlers to ensure most cost-effective, flexible dispensing
• Flexible operations: Exploring the paradigms, challenges and examples within fragment/high concentration compounds and antibody screening

Mark J Wigglesworth
Manager, Lead Optimisation, Sample Management Technologies
GlaxoSmithKline

16.10 Chairperson’s Closing Remarks And Close Of Conference

16.20 Titian Software’s 2010 Annual User Group Meeting

Titian’s User Group Meeting, for users of Titian Software’s “Mosaic” sample management platform, will run back-to-back with IQPC’s 7th Annual Compound Management & Integrity Conference. The Titian UGM will begin at 4PM on Wednesday 19th May, and will continue on Thursday 20th May, with presentations from existing Titian customers and staff members, plus focused roundtable discussion groups. By sharing experiences with other users, and gaining access to Titian’s inhouse expertise, you can maximise the capabilities of your Mosaic software. Away from the more structured presentations, the UGM dinner is an opportunity to meet industry colleagues and network in a more informal atmosphere.

This is a privately held, invitation only meeting. www.titian.co.uk